Expansion Opportunity Leverage LifeCell as part of the Acelity family to cross-sell advanced wound care and regenerative tissue products to hospitals and clinics globally, capitalizing on Acelity’s established presence in over 80 countries and leadership in negative pressure therapy.

Portfolio Synergy Position ALLODERM and REVOLVE offerings alongside other Acelity therapies to address post-surgical reconstruction and fat transfer needs, creating bundled solutions for breast reconstruction, hernia repair, and soft tissue regeneration.

Financial Gateways Target mid-market to large healthcare systems with revenue in the hundreds of millions to align with LifeCell and Acelity’s robust product lineup, focusing on closed-loop procurement, and total cost of care reductions through faster healing and fewer complications.

Innovation Pipeline Highlight ongoing advancements and recent product launches within the Acelity portfolio (such as new incision management and wound care devices) as opportunities to upsell adjunct technologies to existing wound care customers.

Strategic Partnerships Engage key decision-makers tied to wound care, reconstructive surgery, and perioperative management, leveraging Acelity’s brand trust to expand adoption of LifeCell matrices and autologous fat grafting solutions in both hospital and outpatient settings.